Skip to main content
. Author manuscript; available in PMC: 2020 Jun 7.
Published in final edited form as: JAMA. 2020 Feb 25;323(8):746–756. doi: 10.1001/jama.2020.0572

Table 2 –

Screen-detected cancers

Obs a Case Lesion detected at AB-MR b Lesion detected at DBT b Breast density Age Type of cancer Largest diameter c (mm) Maximum reported grade c ER c PR c HER2 c BCSC 5-year risk score BCSC 10-year risk score
1 1 + + ACR-C 62 DCIS 15 2 Positive Positive Not performed 2.79 5.62
2 2 + ACR-C 69 DCIS 20 2 Positive Positive Not performed 3.24 6.17
3 3 + ACR-C 68 DCIS 10 2 Positive Negative Not performed 4.64 8.82
4 4 + ACR-C 71 DCIS 10 3 Positive Negative Not performed 2.10 3.95
5 5 + ACR-C 68 DCIS 5 3 Not performed Not performed Not performed 2.08 4.02
6 6a + ACR-D 63 DCIS 30 2 Positive Not performed Not performed 3.40 6.77
7 7d +d ACR-D 40 DCIS 70 3 Positive Positive Not performed 1.25 3.13
8 8 + ACR-B 62 IDC 4 1 Positive Positive Negative 2.04 4.13
9 9 + ACR-B 65 ILC 16 2 Positive Negative Negative 1.50 2.97
10 10a + + ACR-C 62 IDC 11 1 Positive Positive Negative 1.92 3.88
11 10b + + ACR-C 62 IDC 9 2 Positive Positive Negative 1.92 3.88
12 11 + ACR-C 72 IDC 8 2 Positive Positive Negative N/A e N/A e
13 12 + ACR-C 67 ILC 14 2 Positive Positive Negative 3.14 6.08
14 13a + + ACR-C 56 ILC 25 2 Positive Positive Negative 2.41 5.07
15 13b + ACR-C 56 ILC 25 2 Not available Not available Not available 2.41 5.07
16 14 + + ACR-C 64 IDC 18 2 Negative Negative Negative 2.89 5.73
17 15 + + ACR-C 48 IDC 10 1 Positive Positive Negative 1.07 2.43
18 16 + ACR-C 47 IDC 10 1 Positive Positive Negative 0.99 2.21
19 17 f + + ACR-C 44 IDC N/A f 2 Positive Positive Negative 1.39 3.28
20 18 + ACR-C 52 IDC 24 3 Negative Negative Positive 1.92 4.19
21 19 + + ACR-C 46 Mixed IDC/ILC 48 1 Positive Positive Negative 0.93 2.16
22 20 + ACR-C 51 IDC 10 3 Positive Negative Negative 2.01 4.41
23 21 + ACR-C 70 IDC 10 2 Positive Negative Negative 4.80 8.96
24 22 + + ACR-C 41 IDC 10 1 Positive Positive Negative 0.61 1.50
25 23 + ACR-D 53 IDC 10 1 Positive Positive Negative 4.83 10.21
26 6b + ACR-D 63 IDC 14 3 Positive Positive Negative 3.40 6.77

AB-MR: Abbreviated breast Magnetic Resonance Imaging; DBT: Digital Breast Tomosynthesis; ER: Estrogen receptor status; PR: Progesterone receptor status; HER2: Human epidermal growth factor receptor 2; DCIS: Ductal carcinoma in situ; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; ACR-B: Scattered fibroglandular densities; ACR-C: Heterogeneously dense breasts; ACR-D: Extremely dense breasts;

a

‘Obs’ signifies a count of each individual cancer, and ‘Case’ signifies each unique participant, where participants with more than one cancer have separate cancers distinguished by ‘a’ and ‘b’ (e.g. 6a, 6b).

b

A ‘+’ denotes that the cancer was detected by the modality; a blank cell denotes that the cancer was not detected by the modality.

c

Grade shown is the highest reported grade across the core and surgical biopsy. For ER, PR, HER2, if either the core or surgical biopsy reported positivity, the value is reported as positive. Largest diameter, ductal carcinoma pattern and invasive pattern are from the surgical pathology. In one case (no. 9), the histologic description of a lobular-invasive cancer corresponded to intermediate grade, although no specific grading information was provided

d

DBT reported 2 lesions which were both of the same pathological lesion (a single 70 mm DCIS).

e

BCSC risk scores could not be computed for this participant due to a previous diagnosis of breast cancer.

f

N/A, not available. This case had invasive disease (IDC) by vacuum assisted core biopsy, but there was no residual cancer in the surgical biopsy specimen which contained only benign changes with atypia. Thus, tumor size data from surgical pathology are not available; however, the lesion size was 11 mm by AB-MR and 9 mm by DBT.